Conditions: Recurrence Smoking Cessation Substance-Related Disorders
Keywords: Relapse Smoking Cessation Substance Abuse
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 104
Healthy volunteers: yes

Brief summary:
This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.

Detailed description:
In this study, the investigators plan to use an experimental model of a lapse, in which volunteers smoke two cigarettes after a brief period of (12-24 hours). The goals of this study are to assess the impact of varenicline on the subjective and reinforcing effects of cigarettes, as well as the latency to resume smoking (relapse) following the lapse exposure.

Arms:
arm 1: Group given placebo. arm 2: Experimental group given varenicline dosing.

Interventions: intervention 1: Varenicline intervention 2: Placebo
Intervention descriptions: intervention 1: Varenicline given twice a day or five weeks. intervention 2: Placebo given twice a day or five weeks.

Protocol document: